Investigational drug · Phase 2
DS-3939a
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "DS-3939a"
First trial start
2023
Aug 18, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DS-3939a", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Locally Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
- Advanced Solid Tumor
- Metastatic Solid Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DS-3939a" as an intervention, largest first.
- First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT05875168 · 590 participants (planned) · Start Aug 18, 2023 · Primary completion Aug 11, 2028
Drug: DS-3939a · For: Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Sarasota, Florida; Locust Grove, Georgia; Westwood, Kansas · 61 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07739966 · 400 participants (planned) · Start Oct 13, 2026 · Primary completion Jul 31, 2030
Drug: DS-3939a; Pembrolizumab and 3 more · For: Solid Tumor; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Los Angeles, California; Tampa, Florida · 76 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity.
Takano K, Yukiura M, Takahashi K, et al. · Mol Cancer Ther 2026
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Daiichi Sankyo.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.